PDF herunterladen
Horm Metab Res 2013; 45(06): 456-462
DOI: 10.1055/s-0032-1331746
Humans, Clinical
© Georg Thieme Verlag KG Stuttgart · New York

Investigations of the Anti-inflammatory Effects of Vitamin D in Adipose Tissue: Results from an In Vitro Study and a Randomized Controlled Trial

L. Wamberg
1   Department of Endocrinology and Internal Medicine MEA, Aarhus University Hospital, Aarhus, Denmark
,
K. B. Cullberg
1   Department of Endocrinology and Internal Medicine MEA, Aarhus University Hospital, Aarhus, Denmark
,
L. Rejnmark
1   Department of Endocrinology and Internal Medicine MEA, Aarhus University Hospital, Aarhus, Denmark
,
B. Richelsen
1   Department of Endocrinology and Internal Medicine MEA, Aarhus University Hospital, Aarhus, Denmark
,
S. B. Pedersen
1   Department of Endocrinology and Internal Medicine MEA, Aarhus University Hospital, Aarhus, Denmark
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 29. August 2012

accepted 26. November 2012

Publikationsdatum:
15. Januar 2013 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Inflammation is a key feature of obesity and type 2 diabetes. The active vitamin D metabolite, 1,25-dihydroxyvitamin D [1,25(OH)2D], modulates the inflammation in vitro. We studied whether inflammation in adipose tissue (AT) cultures could be reduced by incubation with 1,25(OH)2D in vitro, or by oral treatment with vitamin D in vivo in obese subjects with low plasma levels of 25-hydroxyvitamin D. Samples of subcutaneous AT were stimulated with IL-1β to induce inflammation. In the in vitro study, samples were concomitantly incubated with or without 1,25(OH)2D, and analyzed for mRNA and protein levels of inflammatory markers IL-6, IL-8, and MCP-1. In the in vivo study, samples of subcutaneous AT from obese subjects obtained before and after treatment with 7 000 IU of vitamin D daily or placebo in a randomized controlled trial were stimulated with IL-1β. The samples were analyzed for AT gene expression and compared with plasma markers of inflammation. In the in vitro study, concomitant incubation with 1,25(OH)2D reduced mRNA levels of MCP-1 by 45% (p=0.01), of IL-6 by 32% (p=0.002), and of IL-8 by 34% (p=0.03), and reduced secretion of IL-8 protein by 18% (p=0.005). In vivo treatment with vitamin D did not reduce AT expression or circulating levels of MCP-1, IL-6, or IL-8. 1,25(OH)2D has significant anti-inflammatory effects in AT in vitro. However, a similar reduction in AT and systemic inflammation cannot be obtained by oral treatment with vitamin D in obese subjects.

Key words

obesity - calcitriol - cytokines - adiponectin
 

  • References

  • 1 Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990–2000. Diabetes 2008; 57: 2619-2625
    CrossrefPubMedGoogle Scholar
  • 2 Kayaniyil S, Vieth R, Retnakaran R, Knight JA, Qi Y, Gerstein HC, Perkins BA, Harris SB, Zinman B, Hanley AJ. Association of Vitamin D With Insulin Resistance and β-Cell Dysfunction in Subjects at Risk for Type 2 Diabetes. Diabetes Care 2010; 33: 1379-1381
    CrossrefPubMedGoogle Scholar
  • 3 Botella-Carretero JI, Alvarez-Blasco F, Villafruela JJ, Balsa JA, Vazquez C, Escobar-Morreale HF. Vitamin D deficiency is associated with the metabolic syndrome in morbid obesity. Clin Nutr 2007; 26: 573-580
    CrossrefPubMedGoogle Scholar
  • 4 Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of Serum Vitamin D and the Metabolic Syndrome Among U.S. Adults. Diabetes Care 2005; 28: 1228-1230
    CrossrefPubMedGoogle Scholar
  • 5 Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004; 27: 2813-2818
    CrossrefPubMedGoogle Scholar
  • 6 Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D’Agostino RB, Wolf M, Vasan RS. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503-511
    CrossrefPubMedGoogle Scholar
  • 7 White JH. Regulation of intracrine production of 1,25-dihydroxyvitamin D and its role in innate immune defense against infection. Arch Biochem Biophys 2012; 523: 58-63
    CrossrefPubMedGoogle Scholar
  • 8 Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808
    CrossrefPubMedGoogle Scholar
  • 9 Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-1830
    CrossrefPubMedGoogle Scholar
  • 10 Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96: 939-949
    CrossrefPubMedGoogle Scholar
  • 11 Feve B, Bastard J-P. The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2009; 5: 305-311
    CrossrefPubMedGoogle Scholar
  • 12 Bruun JM, Pedersen SB, Richelsen B. Regulation of Interleukin 8 Production and Gene Expression in Human Adipose Tissue in Vitro. J Clin Endocrinol Metab 2001; 86: 1267-1273
    CrossrefPubMedGoogle Scholar
  • 13 Olholm J, Paulsen SK, Cullberg KB, Richelsen B, Pedersen SB. Anti-inflammatory effect of resveratrol on adipokine expression and secretion in human adipose tissue explants. Int J Obes (Lond) 2010; 34: 1546-1553
    CrossrefPubMedGoogle Scholar
  • 14 Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, Kasuga M. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116: 1494-1505
    CrossrefPubMedGoogle Scholar
  • 15 Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, Kubota N, Ohtsuka-Kowatari N, Kumagai K, Sakamoto K, Kobayashi M, Yamauchi T, Ueki K, Oishi Y, Nishimura S, Manabe I, Hashimoto H, Ohnishi Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Nagai R, Kadowaki T. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 2006; 281: 26602-26614
    CrossrefPubMedGoogle Scholar
  • 16 Christiansen T, Richelsen B, Bruun JM. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int J Obes 2005; 29: 146-150
    CrossrefPubMedGoogle Scholar
  • 17 Bruun J, Verdich C, Toubro S, Astrup A, Richelsen B. Association between measures of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and tumor necrosis factor-alpha. Effect of weight loss in obese men. Eur J Endocrinol 2003; 148: 535-542
    CrossrefPubMedGoogle Scholar
  • 18 Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. AJP – Endocrinol Metab 2001; 280: E745-E751
    PubMedGoogle Scholar
  • 19 Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J-i, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity. Biochem Biophys Res Commun 1999; 257: 79-83
    CrossrefPubMedGoogle Scholar
  • 20 Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev 2005; 6: 13-21
    CrossrefPubMedGoogle Scholar
  • 21 Trujillo ME, Scherer PE. Adiponectin – journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005; 257: 167-175
    CrossrefPubMedGoogle Scholar
  • 22 Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol 2004; 219: 9-15
    CrossrefPubMedGoogle Scholar
  • 23 Holick MF. Vitamin D Deficiency. N Engl J Med 2007; 357: 266-281
    CrossrefPubMedGoogle Scholar
  • 24 Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW. The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed. J Bone Miner Res 1998; 13: 325-349
    CrossrefPubMedGoogle Scholar
  • 25 Zhang Z, Yuan W, Sun L, Szeto FL, Wong KE, Li X, Kong J, Li YC. 1,25-Dihydroxyvitamin D3 targeting of NF-kappaB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int 2007; 72: 193-201
    CrossrefPubMedGoogle Scholar
  • 26 Zhang Y, Leung DYM, Richers BN, Liu Y, Remigio LK, Riches DW, Goleva E. Vitamin D Inhibits Monocyte/Macrophage Proinflammatory Cytokine Production by Targeting MAPK Phosphatase-1. J Immunol 2012; 188: 2127-2135
    CrossrefPubMedGoogle Scholar
  • 27 Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I, Galaktidou G. Paricalcitol reduces basal and lipopolysaccharide-induced (LPS) TNF-α and IL-8 production by human peripheral blood mononuclear cells. Int Urol Nephrol 2010; 42: 181-185
    CrossrefPubMedGoogle Scholar
  • 28 Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C. Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res Clin Pract 2007; 77: 47-57
    CrossrefPubMedGoogle Scholar
  • 29 Cohen ML, Douvdevani A, Chaimovitz C, Shany S. Regulation of TNF-alpha by 1alpha,25-dihydroxyvitamin D3 in human macrophages from CAPD patients. Kidney Int 2001; 59: 69-75
    CrossrefPubMedGoogle Scholar
  • 30 Bao BY, Yao J, Lee YF. 1à 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 2006; 27: 1883-1893
    CrossrefPubMedGoogle Scholar
  • 31 Nonn L, Peng L, Feldman D, Peehl DM. Inhibition of p38 by Vitamin D Reduces Interleukin-6 Production in Normal Prostate Cells via Mitogen-Activated Protein Kinase Phosphatase 5: Implications for Prostate Cancer Prevention by Vitamin D. Cancer Res 2006; 66: 4516-4524
    CrossrefPubMedGoogle Scholar
  • 32 Lorente-Cebrian S, Eriksson A, Dunlop T, Mejhert N, Dahlman I, Astrom G, Sjolin E, Wahlen K, Carlberg C, Laurencikiene J, Heden P, Arner P, Ryden M. Differential effects of 1alpha,25-dihydroxycholecalciferol on MCP-1 and adiponectin production in human white adipocytes. Eur J Nutr 2012; 51: 335-342
    CrossrefPubMedGoogle Scholar
  • 33 Wamberg L, Richelsen B, Pedersen SB, Rejnmark L. The effect of high-dose vitamin D supplementation on calcitropic hormones and bone mineral density in obese subjects with low levels of circulating 25-hydroxy-vitamin D – results from a randomized controlled study. Calcif Tissue Int 2012 Submitted
    PubMedGoogle Scholar
  • 34 Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112: 1785-1788
    CrossrefPubMedGoogle Scholar
  • 35 Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867
    CrossrefPubMedGoogle Scholar
  • 36 Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887
    CrossrefPubMedGoogle Scholar
  • 37 Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91
    CrossrefPubMedGoogle Scholar
  • 38 Bruun JM, Lihn AS, Pedersen SB, Richelsen Br. Monocyte Chemoattractant Protein-1 Release Is Higher in Visceral than Subcutaneous Human Adipose Tissue (AT): Implication of Macrophages Resident in the AT. J Clin Endocrinol Metab 2005; 90: 2282-2289
    CrossrefPubMedGoogle Scholar
  • 39 Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Llorca J. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 83-86
    PubMedGoogle Scholar
  • 40 Rostkowska-Nadolska B, Sliupkas-Dyrda E, Potyka J, Kusmierz D, Fraczek M, Krecicki T, Kubik P, Zatonski M, Latocha M. Vitamin D derivatives: calcitriol and tacalcitol inhibits interleukin-6 and interleukin-8 expression in human nasal polyp fibroblast cultures. Adv Med Sci 2010; 55: 86-92
    PubMedGoogle Scholar
  • 41 Lira F, Rosa J, Cunha C, Ribeiro E, Oller do Nascimento C, Oyama L, Mota J. Supplementing alpha-tocopherol (vitamin E) and vitamin D3 in high fat diet decrease IL-6 production in murine epididymal adipose tissue and 3T3-L1 adipocytes following LPS stimulation. Lipids Health Dis 2011; 10: 37
    CrossrefPubMedGoogle Scholar
  • 42 Wamberg L, Christiansen T, Paulsen SK, Fisker S, Rask P, Rejnmark L, Richelsen B, Pedersen SB. Expression of vitamin D-metabolizing enzymes in human adipose tissue – the effect of obesity and diet-induced weight loss. Int J Obes 2012; DOI: 10.1038/ijo.2012.112.
    PubMedGoogle Scholar
  • 43 Matilainen JM, Husso T, Toropainen S, Seuter S, Turunen MP, Gynther P, Yla-Herttuala S, Carlberg C, Vaisanen S. Primary effect of 1alpha,25(OH)D on IL-10 expression in monocytes is short-term down-regulation. Biochim Biophys Acta 2010; 1803: 1276-1286
    CrossrefPubMedGoogle Scholar
  • 44 Lee BN, Kim TH, Jun JB, Yoo DH, Woo JH, Choi SJ, Lee YH, Song GG, Kim Y, Lee JY, Sohn J, Ji JD. Upregulation of interleukin-1beta production by 1,25-dihydroxyvitamin D(3) in activated human macrophages. Mol Biol Rep 2011; 38: 2193-2201
    CrossrefPubMedGoogle Scholar
  • 45 Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, Vasan RS, Murabito JM, Meigs JB, Cupples LA, D’Agostino Sr RB, O’Donnell CJ. Abdominal Visceral and Subcutaneous Adipose Tissue Compartments: Association With Metabolic Risk Factors in the Framingham Heart Study. Circulation 2007; 116: 39-48
    CrossrefPubMedGoogle Scholar
  • 46 Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care 2007; 30: 980-986
    CrossrefPubMedGoogle Scholar
  • 47 Jorde R, Sneve M, Torjesen PA, Figenschau Y, Goransson LG, Omdal R. No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine 2010; 50: 175-180
    CrossrefPubMedGoogle Scholar
  • 48 Zittermann A, Frisch S, Berthold HK, Gotting C, Kuhn J, Kleesiek K, Stehle P, Koertke H, Koerfer R. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr 2009; 89: 1321-1327
    CrossrefPubMedGoogle Scholar
  • 49 Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011; 96: 1911-1930
    CrossrefPubMedGoogle Scholar
  • 50 Lagunova Z, Porojnicu AC, Vieth R, Lindberg FA, Hexeberg S, Moan J. Serum 25-Hydroxyvitamin D Is a Predictor of Serum 1,25-Dihydroxyvitamin D in Overweight and Obese Patients. J Nutr 2011; 141: 112-117
    CrossrefPubMedGoogle Scholar
  • 51 Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM, Hewison M. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001; 86: 888-894
    CrossrefPubMedGoogle Scholar
  • 52 Ching S, Kashinkunti S, Niehaus MD, Zinser GM. Mammary adipocytes bioactivate 25-hydroxyvitamin D3 and signal via vitamin D3 receptor, modulating mammary epithelial cell growth. J Cell Biochem 2011; 112: 3393-3405
    CrossrefPubMedGoogle Scholar
  • 53 Li J, Byrne ME, Chang E, Jiang Y, Donkin SS, Buhman KK, Burgess JR, Teegarden D. 1alpha,25-Dihydroxyvitamin D hydroxylase in adipocytes. J Steroid Biochem Mol Biol 2008; 112: 122-126
    CrossrefPubMedGoogle Scholar